FindTrial
Sign In

PTK787/ZK 222584

DRUG6 trials

Sponsors

Novartis Pharmaceuticals, Alliance for Clinical Trials in Oncology, Washington University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital

Conditions

CNS HemangioblastomaGlioblastomaMalignant MesotheliomaMelanomaMetastatic Non-hematologic MalignanciesMultiple MyelomaRetinal HemangioblastomaVon Hippel-Lindau Disease

Phase 1

Trial of PTK787/ZK 222584 Plus Paclitaxel
TerminatedNCT00358163
Dana-Farber Cancer InstituteMetastatic Non-hematologic Malignancies
Start: 2006-04-26End: 2008-05-29Updated: 2022-04-29
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
CompletedNCT00385853
Massachusetts General HospitalGlioblastoma
Start: 2006-09-30End: 2011-09-30Updated: 2013-10-21
PTK/ZK in Disseminated Malignant Melanoma
TerminatedNCT00615160
Michael WeichenthalMelanoma
Start: 2006-12-31End: 2008-09-30Updated: 2021-10-06

Phase 2

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
CompletedNCT00052013
Novartis PharmaceuticalsCNS Hemangioblastoma, Retinal Hemangioblastoma, Von Hippel-Lindau Disease
Start: 2003-02-28Updated: 2017-03-06
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
CompletedNCT00053885
Alliance for Clinical Trials in OncologyMalignant Mesothelioma
Start: 2003-07-31End: 2006-06-30Updated: 2016-07-01
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
TerminatedNCT00240162
Washington University School of MedicineMultiple Myeloma
Start: 2005-09-30End: 2008-12-31Updated: 2014-09-17

Related Papers

177P The immune-microenvironment confers chemoresistance in breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Immuno-Oncology Technology2023-12-01